Denis Bedoret is the founder of Imcyse. Imcyse has raised $65M in total funding. Latest round: Series B. Backed by Biogenosis, Epimede, KU Leuven.
Denis Bedoret was appointed CEO of Imcyse in September 2020. Imcyse is a clinical-stage biopharmaceutical company based in Liège, Belgium, founded in 2010 as a spin-off from KU Leuven. The company develops active specific immunotherapies using its Imotope™ technology platform, targeting severe chronic autoimmune diseases like type 1 diabetes and multiple sclerosis. Imcyse has raised $64.6 million across two funding rounds, with its most recent being a $25.8 million Series B Extension in February 2021.
Full founder directory · Investor directory · Company funding database · Fundraising library